You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
SharePoint
Sign In
Follow
ECC-PICO
Currently selected
SEERS
2019 Cape Town Meeting Documents
PublicComment
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Libraries
2018 Chicago Meeting Documents
2017 ILCOR Anaheim Meeting Documents
PICO Search Re-runs
2017 ILCOR Adelaide Meeting Documents
Evidence Review Process
Newcastle
Lists
Recent
Currently selected
ILCOR 2019 Cape Town Meeting Documents
2018 Chicago Meeting Documents
Feedback
If you have any comments or questions on this page, please email us at:
ILCORC2015@heart.org
Lipid Therapy for Cardiac Arrest
Question Type:
Intervention
Digital Worksheet:
Open the Digital Worksheet to find more information on the development of this CoSTR.
Full Question:
In adult patients with cardiac arrest due to suspected drug toxicity (eg, local anesthetics, tricyclic antidepressants, others) (P), does does administration of IV lipid (I), compared with compared with no IV lipid (C), change Survival with Favorable neurological/functional outcome at discharge, 30 days, 60 days, 180 days AND/OR 1 year, Survival only at discharge, 30 days, 60 days, 180 days AND/OR 1 year, ROSC (O)?
Consensus on Science:
We identified no human comparative studies in cardiac arrest and periarrest states relevant to the PICO question. Many case reports and case series described resuscitation that included administration of lipid.
Treatment Recommendation:
We are unable to make any evidence-based treatment recommendation about the use of IV lipid emulsion to treat toxin-induced cardiac arrest. Values, Preferences, and Task Force Insights Although there are many case reports and case series of patients who were resuscitated after administration of IV lipid, the absence of any comparative data made it impossible to determine anything besides temporal association of the therapy with outcome. Despite the paucity of data, we do not wish to discourage the use of an antidote with some theoretical basis in a dire clinical situation.
CoSTR Attachments:
ALS-834 Lipid Therapy for Cardiac Arrest 2015-02-03 posted for public comment.pdf
Contact Us
If you have any comments or questions on this page, please email us at:
ILCORC2015@heart.org